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 ABSTRACT 
Overactive Bladder (OAB) is a symptom syndrome characterized by urgency and 
frequency, with or without urge incontinence. Research concerning the mechanisms 
underlying OAB and finding new inhibitory factor(s) is intensive.  
 
By using a cascade superfusion system, we confirmed the existence of urothelium-
derived inhibitory activity in the guinea pig urinary bladder. The unknown inhibitory 
activity was transmissible over a significant distance, thus allowing attempts at 
isolation. The unknown factor(s) was found unlikely to be nitric oxide, an adenosine 
receptor agonist or cyclo-oxygenase products.  
 
During isolation of the unknown transmissible inhibitory factor(s) using HPLC and 
bioassay technologies, we observed considerable amounts of PGE2 and PGD2 being 
released from guinea pig urinary bladder urothelium, in the resting state. PGE2 and 
PGD2 were not only released from the bladder but also exerted modulatory effects 
regulating the lower urinary tract motility.  
 
Organ bath experiments using pharmacological tools in guinea pig urothelium-denuded 
bladder strips showed that PGE2 increased basal tone and spontaneous contractions. 
Exogenous PGE2 potentiated contractile responses to EFS, ACh and ATP, while PGD2 
caused inhibition of EFS, ACh and ATP induced contractions. The inhibitory effect of 
PGD2 was exerted via DP1 receptors as judged from agonist and antagonist 
experiments. PGD2 also had a low affinity excitatory effect via TP receptors.  
 
The bladder trigone and urethra have different innervations compared with the bladder 
dome. Both trigone and proximal urethra are important in continence. The effects of 
PGE2 and PGD2 were investigated also in these regions in the guinea pig. PGE2 and 
PGD2 in a dose-dependent manner inhibited trigone contractions induced by EFS and 
spontaneous contractions of the proximal urethra. 
 
Immunohistochemical studies of DP1 and DP2 receptor proteins indicated that DP1 and 
DP2 receptors were localized in the guinea pig bladder dome, trigone and urethra. Both 
urothelium/sub-urothelium and smooth muscle cells were immunolabelled with DP1 
and DP2 receptor antibodies. Hematopoietic prostaglandin D synthase was abundant in 
the immediate sub-urothelium. 
 
These findings will be of importance in understanding normal function and 
pathophysiology of the lower urinary tract, hopefully opening up new future treatment 
modalities. 
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1 INTRODUCTION 
 
1.1 LOWER URINARY TRACT SYMPTOMS 
In 2003, the standardization sub-committee of the International Continence Society 
(ICS) issued the latest report of the standardization of terminology in lower urinary 
tract function (Abrams et al., 2003). This updated version included all the new and 
changed definitions of previous ICS reports. The terminology covered the definitions of 
lower urinary tract symptoms, signs suggestive of lower urinary tract dysfunction, 
urodynamic observations, conditions and treatment. Symptoms are defined as the 
subjective indicators of a disease or change in condition witnessed by the patient, 
caregiver or persons around and may result in seeking help from professionals. There 
are three groups of lower urinary tract symptoms: storage symptoms, voiding 
symptoms and post micturition symptoms. 
 
1.1.1 Storage Symptoms 
The bladder relaxes and stores urine for more than 99% of the lifetime. Storage 
symptoms are experienced during the storage phase of the bladder and include 
increased daytime frequency, nocturia (frequency during sleep), urgency and urinary 
incontinence (not applicable to infants and small children).  
 
1.1.2 Voiding and Post Micturition Symptoms 
Voiding symptoms are experienced during the voiding phase which include slow 
stream, splitting or spraying of urine stream, intermittent stream, hesitancy, straining to 
void and terminal dribble.  
Post micturition symptoms are experienced immediately after micturition including 
feeling of incomplete emptying and post micturition dribble. 
 
Lower urinary tract symptoms also include the symptoms associated with sexual 
intercourse, with pelvic organ prolapse, genital and lower urinary tract pain etcetera. 
 
1.1.3 OAB 
The ICS committee recommended the use of overactive bladder syndrome and detrusor 
overactivity after 2002 ICS standardization of lower urinary tract function/dysfunction 
terminology (Abrams et al., 2002; Abrams, 2003). Detrusor overactivity is an 
urodynamic diagnosis which defines the signs and symptoms during urodynamic 
observation. The report described two types of detrusor overactivity: phasic and 
terminal. In order to simply describe the condition, the term “Overactive Bladder 
(OAB) Symptom Complex” has been introduced. OAB is a symptomatic diagnosis 
with the definition as urgency, with or without urge incontinence, usually with 
increased daytime frequency and nocturia (Abrams et al., 2002). However, OAB is not 
synonymous with detrusor overactivity. A study among 1457 patients showed that 82% 
of men with OAB had detrusor overactivity (sensitivity) and 82% with detrusor 
overactivity had OAB (positive predictive value), while the rate for women were 58% 
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and 85% respectively (Hashim et al., 2006). The bladder seems to be a more reliable 
witness in men than in women (op.cit.). 
 
OAB affects nearly 34 million in the US and 66 million people in the European Union 
One epidemiological study concerning the prevalence of overactive bladder syndrome, 
before the ICS 2002 definition and among 16776 interviews, in six European counties 
found the overall prevalence of overactive bladder symptoms in individuals above age 
40 was 16.6% (15.6% of men and 17.4% of women) (Milsom et al., 2001). Later it was 
believed that this number was too high (Hashim et al., 2007). Many other studies 
regarding the overactive bladder syndrome prevalence showed similar results. The 
National Overactive Bladder Evaluation (NOBLE) Program using a sample of 5204 
adults over age 18 revealed an OAB prevalence of 16.0% in men and 16.9% in women 
in the United States (Stewart et al., 2003). A population-based study of OAB symptoms 
among 1000 adults of age over 18 reported 13.9% (13.1% in men and 14.7% in 
women) prevalence in Canada (Herschorn et al., 2008). Among 1827 community-
dwelling adults in Taiwan, the age-adjusted prevalence of OAB was 16.9% (Yu et al., 
2006). The largest multinational population-based study was the EPIC study using the 
current ICS definition included Canada, Germany, Italy, Sweden and the United 
Kingdom. The overall prevalence of OAB was 11.8% within the 19165 participating 
individuals. Rates were similar in men and women and increased with age (Irwin et al., 
2006a). A recently study limited to individuals aged 40 and older from US, UK and 
Sweden showed that the prevalence of OAB ranged from 26-33% across races for men 
and from 27-46% for women (Coyne et al., 2012).(Figure 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Ring diagram showing that the average prevalence of OAB from cited studies 
was about 15% of the entire population. 80% of the OAB patients expressed frequency 
especially nocturia, 50% of the OAB patients reported urgency and 30% had urge 
incontinence symptom. OAB dry, the term from the NOBLE study defining the 
individuals who had OAB symptoms but no urge incontinence, was more prevalent in 
men. OAB wet was more prevalent in women which might be due to weak bladder neck 
and sphincter mechanism. 
 
Although OAB symptoms conditions are not life threatening, they seriously affect 
quality of life of the individual, including employment, social interactions and 
Urge incontinence 
Frequency 
OAB 
Wet 
(urge, stress, mixed) 
OAB 
Dry 
Urgency (key symptom) 
OAB ≈15% of population 
≈ 80% of OAB 
≈ 50% of OAB 
≈ 30% of OAB 
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emotional well-being (Irwin et al., 2006b). Frequency and urge incontinence also 
increase the risk of urinary tract infection and falls (Brown et al., 2000). OAB patients 
with nocturia suffering from poor sleeping quality had lower level of vitality (Kobelt et 
al., 2003). These lower urinary tract symptoms are more prevalent in the older 
population, where 40% of individuals over the age of 70 are affected (Milsom et al., 
2001). As a consequence, OAB produces major problems for individuals, health 
professions and society. Importantly, as people are generally living longer, the numbers 
of affected people are increasing. It is obvious that the combined problems give a heavy 
economic burden to the society. The main costs include treatment costs, routine care 
costs, consequences costs and indirect costs (Hu et al., 2004). The mainly non-
pharmacotherapeutic costs can thus lead to an under-estimation of the financial 
magnitude of the problem. It has been indicated that the estimated total cost of urinary 
incontinence and OAB was $19.5 billion and $12.6 billion respectively in the United 
States in year 2000 using data from the NOBLE program (Hu et al., 2004). In 2007, 
OAB resulted in total costs of $65.9 billion in the US with projected total national costs 
of $76.2 billion and $82.6 billion respectively in year 2015 and 2020 (Ganz et al., 
2010). In a report covering Germany alone, 6.48 million adults over 40 years of age 
were affected by OAB, and 2.18 million of these individuals experience incontinence, 
with annual financial implications in the range of €3.98 billion, costs comparable to 
other chronic diseases such as dementia or diabetes mellitus (Klotz et al., 2007). 
Estimation of the economic costs of OAB in six countries (Canada, Germany, Italy, 
Spain, Sweden and the UK) by using the prevalence data from the EPIC study and 
healthcare resource-use data showed the total annual direct cost plus nursing care and 
work absenteeism cost was €9.7 billion (Irwin et al., 2009). The direct cost in Sweden 
was estimated to be €333 million per year.  
 
The primary clinical problem and major impact to the patient is urgency to void 
(Abrams et al. 2002). The ICS definition of urgency is the complaint of a sudden 
compelling desire to pass urine which is difficult to defer. Urgency is the key symptom 
and must be a symptom for OAB diagnosis and is also the driver for other lower 
urinary tract symptoms (Abrams et al., 2012). Remarkably, despite the prevalence and 
costs involved, the mechanisms underlying urgency are currently unknown. There are 
three main pathophysiology theories about OAB and detrusor overactivity: myogenic 
theory (Brading, 1997), neurogenic theory (de Groat, 1997) and autonomous bladder 
theory (Drake et al., 2001). These theories all involve the unbalanced release of 
inhibitory and excitatory neurotransmitters or modulating mediators. Little 
understanding of the mechanism leads to the lack of effective pharmacological 
treatment. Antimuscarinic drugs are the most commonly used agents to treat OAB, but 
their clinical utility is limited due to side effects and low efficacy. Undoubtedly, there 
are needs for exploring the mechanisms underlying this process and finding new 
therapeutic targets to treat OAB effectively. 
 
OAB debate 
Debate on the definition of OAB as a symptom syndrome has been continuing since it 
was first issued in the report by the standardization committee of International 
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Continence Society in 2002. Among all the OAB debates, the main arguments are 
whether the concept of OAB simplifies the clinical conditions, with their different 
causes, underlying ‘overactive bladder’ patients (Zinner, 2011; Tikkinen et al., 2012) 
and if the concept of OAB was created by the pharmaceutical industry as marketing 
method to sell drugs (Tikkinen et al., 2012).  
In my opinion, the driving force of issuing the descriptive term OAB is not the above 
debates but medical needs behind. Before the concept of OAB was introduced, similar 
medical conditions were referred to as unstable bladder which is a urodynamic 
diagnosis. In the clinic, many patients are hesitant to undergoing the urodynamic test 
before receiving any drug treatments. Though OAB describes a set of symptoms which 
does not provide any pathophysiological explanation, there is a need for finding a term 
that patients, nurses, and doctors can easily understand and use it to begin empirical 
management. By using the term OAB, more attention will be brought into the scientific 
fields and more research concerning the mechanisms behind OAB will be done. This 
will lead to modifications of and more accurate description of overactive bladder 
conditions. Already in the seventies, emepronium bromide and later terodiline as 
anticholinergic drugs were introduced in urology to treat smooth muscle overactive 
conditions. Due to severe side effects, these drugs were abandoned in many countries. 
This led to the need of new anticholinergic drugs with less side effects such as 
tolterodine and to find new drugs that target on other signaling pathways. Despite 
having some utility in OAB, many patients are not treated effectively even with the 
most recent agents (Ko et al., 2006), despite supporting reports (Van Kerrebroeck et al., 
2001; Nabi et al., 2006).  
 
 
1.2 LOWER URINARY TRACT ANATOMY AND PHYSIOLOGY 
The lower urinary tract consists of the bladder and urethra. The bladder is a hollow 
muscular organ to collect and store urine generated by the kidneys. The structure of the 
bladder is similar between male and female. The urethra is directly connected to the 
bladder and is a somewhat muscular passage for micturition. The structure and function 
of urethra is different between the male and female. In the male, genital glands are 
connected and have openings towards the urethra which thus carries semen and other 
fluids ejaculated from genital ducts, as well as urine. In the female, the urethra is 
shorter and only responsible for urination. Besides gender differences, there are also 
species variation between the human and other mammals. 
 
1.2.1 Gross Anatomy of Bladder and Urethra 
 
Bladder  
The bladder is a distensible organ in the pelvis. The size and shape of the bladder 
change when it fills with different volumes of urine. In healthy adults, the bladder can 
hold 300-500 ml of urine. The bladder wall consists of several layers. The internal 
surface is lined with transitional epithelium (urothelium), which becomes thinner and 
flatter during bladder distension and folds when the bladder is empty. The urothelium 
has three layers with different cell types, the apical umbrella cells, the intermediate 
cells and basal cells (Richter et al., 1963). The lamina propria underlying the 
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urothelium is a collagenous fibroelastic connective tissue rich in blood vessels, nerves, 
interstitial cells and some muscle bundles. The ensuing smooth muscle layer (detrusor) 
which accounts for the most of the bladder wall, mixed with connective tissue, forms 
parallel muscle bundles. These smooth muscle bundles are irregularly oriented, loosely 
arranged into inner longitudinal, middle circular, and outer longitudinal layers. The 
inner and outer layers are not clearly separated; muscle bundle can cross layers and 
branch into a longitudinal or circle direction. 
 
The bladder trigone is defined as the region within the three openings: two ureters and 
urethra. This region is relatively smooth and constant in thickness compared with the 
rest of the bladder. The trigone is composed of three muscle layers: a superficial layer, 
derived from the longitudinal muscle of the ureter extending into the urethra, a deep 
layer and a detrusor layer originally coming from the bladder outer longitudinal and 
middle circular smooth muscle layers.  
 
Bladder neck  
Smooth muscle cells in the bladder neck become smaller in size and the muscle bundles 
are more uniformly organized. The smooth muscle around the bladder neck is 
morphologically and pharmacologically distinct from the remainder of the bladder. The 
anterior of the bladder neck is more closely akin to the bladder detrusor muscle, while 
the posterior fibers are more similar to the trigone (Gosling et al., 1987; Delancey et al., 
2002). The structure of the bladder neck seems to differ between men and women. In 
male, three distinct layers of smooth muscle are present: inner layer of longitudinal 
smooth muscle bundles continuous with the inner longitudinal layer of the urethra, the 
middle circular layer that becomes the proximal sphincter at the bladder neck level, and 
the outer longitudinal layers. At the female bladder neck, the majority of muscle 
bundles extend obliquely or longitudinally into the urethral wall and the existence of 
sphincter like circular muscle layer is debatable (Chung et al., 2012) 
 
Urethra 
The length of the human male urethra is approximately 20 cm and is usually described 
as three parts: prostatic, membranous and spongy. The female urethra is a 
fibromuscular tube only about 3-4 cm long. The urethra is lined with transitional 
epithelium which changes to a nonkeratinized stratified squamous epithelium in the 
very distal end of the female urethra. The lamina propria separates the urothelium and 
muscle layer and has many fibroblasts, small glands, blood vessels and nerves. 
Compared with bladder detrusor, the muscle bundle cells are relatively small and 
interspersed with large amounts of connective tissue. A continuation of bladder inner 
longitudinal smooth muscle forms the inner longitudinal smooth layer of urethra and 
runs the entire course of the urethra. The bladder outer longitudinal muscle cells travel 
obliquely around bladder neck and proximal urethra. As a result, the longitudinal 
arranged muscle cells become more and more circular from the neck to urethra. This 
urethra outer circular smooth muscle layer is only present in the proximal urethra, 
which ends at where it meets the striated muscle that forms the intrinsic 
rhabdosphincter (Hutch et al., 1968). In the male, the outer circular smooth muscle 
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fuses with the ventral face of the prostate in the prostatic urethra region. The outer 
circular muscle only covers the anterior part of the proximal urethra, while in female 
the proximal urethra is surrounded by outer circular smooth muscle. Due to the 
anatomical position of the male prostate and the female vaginal wall, the superior part 
of striated muscle only covers the anterior part of the urethra. The inferior part of the 
striated muscle becomes horseshoe-shaped and covers the anterior and posterior of the 
urethra. In the female, the distal part of the striated muscle extends and covers the 
urethra and vagina (Yucel et al., 2004; Wallner et al., 2009). 
 
Urethral sphincter 
The muscular sphincters in the male prostatic + membranous urethra and the proximal 
60% of the female urethra are especially implicated in urinary continence. Two major 
sphincter mechanisms are described in this region: the internal urethral sphincter and 
the external urethral sphincter (intrinsic rhabdosphincter for the striated component). 
The internal sphincter is located at the junction of the urethra with the bladder. The 
internal sphincter is a continuation of the bladder smooth muscle. The external 
sphincter is located at the 15 to 60% of the proximal urethra in females and at the level 
of the membranous urethra in the male. The external sphincter consists of an outer 
striated muscle and an inner longitudinal thin layer of smooth muscle. (Figure 2) 
 
 
 
 
 
Figure 2. Schematic drawing of different muscle layers arranged in the male (left) and 
female (right) bladder and urethra. The external urethra sphincter is composed of 
urethral inner longitudinal smooth muscle, which extends from bladder inner 
longitudinal detrusor, and of outer striated muscle. The outer longitudinal detrusor 
muscle bundles extend obliquely into the urethral wall. As a result, muscle bundles 
travel across to the other side of the bladder to become circularly oriented. This 
sphincter-like circular muscle layer is referred to as the internal urethra sphincter. 
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Male guinea pig lower urinary tract 
Many different kinds of mammals are used to study the function of the lower urinary 
tract. However, the anatomy, pathophysiology and pharmacology might not be the 
same at all. When performing animal experiments, it is important to be aware of the 
differences. Guinea pigs are widely used for both in vivo and in vitro studies on the 
biological function of the urinary tract. Studies have shown the basic structure of the 
guinea pig LUT to be comparable to the human. However, the accessory glands and 
gland locations are different and it does not seem to be the right model to study the 
glands related diseases (Figure 3). The sphincter mechanisms to maintain continence 
are comparable to human, and it might be suitable to use guinea pig isolated muscle 
strips or cell cultures in this context (Neuhaus et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cartoon showing the locations and structural relations of elements in male 
guinea pig lower urinary tract and accessory glands. The bladder in the figure is 
empty. The prostate glands have several lobes as in the human, but they do not 
surround the proximal urethra lumen. The coagulating glands are unique for rodents 
and do not exist in the human. The prostate glands, coagulating glands, seminal 
vesicles and vas deferens all discharge through the dorsal wall of the proximal urethra.  
 
 
1.2.2 Innervation  
 
The efferent innervation 
A complex network of efferent (motor) and afferent (sensory) signaling in the 
autonomic and somatic nervous system is involved in regulating the lower urinary tract 
function. The cerebral cortex, brain stem and spinal cord are all involved in the central 
nervous system control. In both male and female, the bladder wall is mainly supplied 
with parasympathetic cholinergic nerve endings derived from the S2-S4 spinal cord 
segments. A nonadrenergic, noncholinergic (NANC) component of the autonomic 
nervous system has been proposed in activating the detrusor. Sparse sympathetic 
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neurons derived from Th10-L2 segments may also participate in mediating detrusor 
relaxation during urine storage. Down along the tract, the male bladder neck receives 
rich sympathetic innervation. In contrast, the female bladder neck has little adrenergic 
innervation. The trigone and male preprostatic sphincter (prevents retrograde 
ejaculation) are the only regions to show a distinct innervation by adrenergic neurons. 
The bladder neck and trigone also receive innervation from nitric oxide synthase 
containing nerves. They both relax during micturition. 
 
Being regulated by both excitatory and inhibitory nerves, the innervation of the urethral 
smooth muscle is in this aspect more complicated than the detrusor. The female urethral 
smooth muscle has relatively few noradrenergic sympathetic nerves but receives an 
extensive presumably cholinergic parasympathetic nerve supply from the spinal cord 
S2-S4 segments similar as in the detrusor. In the pig urethra, it was suggested that two 
independent components were involved in the NANC-nerve derived urethral relaxation, 
one of which being nitrergic nerves, the other is still unknown (Werkström et al., 
1995). Urethral smooth muscle is activated in a stimulatory and inhibitory fashion to 
become shortened and widened during micturition. Similar preganglionic 
parasympathetic innervation to the smooth muscle components of the membranous 
urethra is likely to be present in the male. The striated muscle of the external urethral 
sphincter receives dual somatic innervations from the pudendal and pelvic somatic 
nerves from S2-S4 nerve roots in both the male and female (Delancey et al., 2002; 
Chung et al., 2012). 
 
The afferent innervation 
Afferent nerves sense stimuli and provide information to the central nervous system. 
Compared with efferent innervation in the lower urinary tract, the afferent innervation 
is less well understood. Many sensations and nervous pathways have been proposed 
arising from bladder and urethra: the sensation of normal filling; the sensation of 
voiding; the sensation of urgency incontinence; the sensation that urine is passing 
(Nathan, 1956). The afferent innervation in human lower urinary tract arises from 
neurons located in the dorsal root ganglia at the level of S2-S4 and Th11-L2 spinal 
segments. Two kinds of afferent fibers are found in the bladder: myelinated A-δ fibers 
and unmyelinated C-fibers. Sensation of bladder filling is conducted by A-δ fibers. C-
fibers synthesize and release various neuropeptides, including calcitonin-gene-related 
peptide (CGRP), vasoactive intestinal polypeptide (VIP), pituitary-adenylate cyclase- 
activating polypeptide (PACAP) and tachykinins (substance P and neurokinin A). C-
fibers also express many neuropeptide receptors and other receptors, including 
acetylcholine, ATP, prostaglandins and transient receptor potential (TRP) receptors (de 
Groat et al., 2009; de Groat et al., 2012). 
In the human, by using immunohistochemistry, peptidergic afferent axons were found 
distributed throughout the bladder and co-located within the subepithelial region, 
encircling ganglia cells and around blood vessels (Smet et al., 1997). In the urethra, the 
afferent nerves were distributed between the muscle fibers, in the urothelium, and 
especially dense in the suburothelial layer (Crowe et al., 1986; Tainio, 1993). The 
striated sphincter muscle seem to have very little afferent innervation. As indicated 
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before, the morphology of striated muscle in human urethra reveals relatively small 
cells compared with skeletal muscle. Specialized tension receptors which are prominent 
in most skeletal muscles were either absent or present in low density in human 
rhabdosphincter (Gosling et al., 1981; Lassmann, 1984). 
 
1.2.3 Bladder Filling and Voiding 
 
Bladder storage 
During bladder filling, the intravesical pressure remains relatively constant until the 
volume reaches the threshold of voiding although there is increasing afferent activity 
during filling. The ability of keeping the pressure stable is a passive phenomenon of 
smooth muscle called compliance together with spinal modulation of the incoming 
afferent signals. Smooth muscle has the intrinsic ability to change length without 
changing tension within a certain range. de Groat proposed a “gating” mechanism that 
might be involved in bladder storage. In short, an inhibitory interneuron mechanism in 
the spinal cord helps to keep afferent impulses, until they reach a threshold, from being 
transmitted into efferent signals. When reaching the threshold, intensive impulses are 
then transmitted down the postganglionic efferent neuron to the bladder resulting in 
smooth muscle contraction (deGroat et al., 1980). In addition, there are inhibitory 
effects of the sympathetic neurons that have postganglionic branches ending on 
parasympathetic ganglion cells in the bladder. This promotes urethral outlet closure and 
inhibits contractions of the bladder (de Groat et al., 1976). During filling, a local spinal 
reflex with an increased efferent firing in the pudendal nerves results in an increased 
outlet resistance. Contractions mediated by pudendal motorneurons in the urethral 
sphincter are activated by bladder afferent input (Park et al., 1997a), and urethral and 
pelvic floor afferent inputs (Fedirchuk et al., 1992). Contraction of the urethral 
sphincter also sends afferent input to activate the central inhibitory mechanisms, further 
suppressing the micturition reflex (McGuire et al., 1983). 
 
Bladder emptying 
When the bladder volume reaches a threshold, a voiding process will be triggered. As 
mentioned above, increased intensive afferent signaling transmits onward to the pons to 
activate the parasympathetic efferent activity and inhibits the sympathetic and somatic 
pathway. This reflex results in sufficient amplitude and duration of contraction to 
empty the bladder and in relaxation of the intrinsic rhabdosphincter to allow voiding. 
The drop of the urethral pressure is not the consequence of bladder contraction as it 
happens before the bladder contraction (Tanagho et al., 1970). An important inhibitory 
transmitter, NO, is released to relax the bladder neck and urethral smooth muscle 
during micturition, a response mediated by activation of a parasympathetic pathway 
(Andersson et al., 1994; Bennett et al., 1995). The activation of the parasympathetic 
pathway to the urethra also counteracts the excitatory inputs to the urethra (Mundy, 
2010; Yoshimura et al., 2010).  
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1.2.4 Peripheral Control of Smooth Muscle  
 
Mechanisms of smooth muscle contraction 
Detrusor smooth muscle cells are spindle shaped single nucleated cells with plasticity 
and diversity. The phasic contraction of the smooth muscle cell is triggered by myosin 
light chain phosphorylation. Inactivation of myosin (dephosphorylation) results in the 
relaxation. The phosphorylation requires Ca2+-calmodulin complex activated myosin 
light chain kinase (MLCK) while dephosphorylation needs myosin light chain 
phosphatase (MLCP). Protein kinase C (PKC) activates the phosphorylation of both 
structural and regulatory components of actin which regulate the tonic contraction 
(Rasmussen et al., 1987). The intracellular free calcium level is the major determinant 
during smooth muscle contractility. Other modulators that may regulate the activity of 
key enzymes can also affect the contraction and relaxation of smooth muscle, including 
cAMP-dependent protein kinase A (PKA), mitogen-activated protein kinase, CaM 
kinase II (Yamaguchi, 2004) and rho-associated kinase (ROK) (Kimura et al., 1996). 
 
Neurotransmitters and modulators 
In healthy human bladder, acetylcholine (ACh) is the contractile neurotransmitter, 
while in many pathologies including OAB, hypertrophy, interstitial cystitis, neurogenic 
damage (Palea et al., 1993; Bayliss et al., 1999), and in physiological signaling of 
many animals (Burnstock et al., 1978), ATP is regarded as an additional activator of 
muscle contraction. The source of ACh is not only parasympathetic and somatic motor 
nerves but also urothelium (Lips et al., 2007). There are five subtypes of muscarinic 
receptors and they are expressed throughout the LUT. In human, rat, rabbit and guinea 
pig detrusor, immunoprecipitation analyses have shown that m2 and m3 subtypes are 
expressed (Wang et al., 1995). Although more m2 receptors are expressed, the 
contractile activity is via m3 subtype. In most mammalian species, ATP is co-released 
with ACh from parasympathetic nerves, which activates P2 (P2X and P2Y) receptors to 
initiate detrusor contraction (Burnstock, 2011). Unlike parasympathetic activation, 
direct sympathetic innervation in detrusor is less important. In pig, few evenly 
distributed adrenergic nerve terminals were found in detrusor, while a greater number 
of terminals were observed in the trigone, bladder neck and urethra (Larsen et al., 
1978). All three beta-receptor subtypes are expressed in detrusor of which β3  is the 
most abundant subtype (Yamaguchi, 2002). Activation of β3 receptors elevates smooth 
muscle cAMP levels and causes detrusor relaxation, making it a potential interesting 
target for OAB treatment (Andersson et al., 2013).  
 
In most species, nitric oxide does not have a role as neurotransmitter to cause direct 
relaxation of the detrusor. The density of nitric oxide synthase (NOS) immunoreactivity 
was higher in trigone and urethra than in the detrusor (Persson et al., 1993). In human 
bladder neck and urethra, the areas of marked relaxations activity to nerve stimulation 
and the areas of high NOS abundance were in good agreement, suggesting nitric oxide 
as a mediator for the neurogenic dilation of the bladder neck and urethra during the 
micturition reflex (Ehrén et al., 1994). The synthesis, storage and release of 
neuropeptides including vasoactive intestinal polypeptide (VIP), calcitonin gene– 
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related peptide (CGRP), substance P, neurokinin A, and pituitary adenylate cyclase-
activating peptide (PACAP) from efferent and afferent nerves and urothelial cells have 
been demonstrated in the lower urinary tract. VIP was shown to inhibit spontaneous 
contractions in isolated detrusor and urethral muscle from human and animals (Sjögren 
et al., 1985). CGRP is contained within capsaicin-sensitive sensory nerves in the 
urinary bladder. CGRP could relax rat bladder neck, and inhibited neuromuscular 
transmission in the guinea pig detrusor. In vivo, high concentrations of CGRP inhibited 
the rat micturition reflex (Hoyle, 1994). Tachykinins (substance P and neurokinin A) 
had contractile effects in the isolated bladder smooth muscle (Negri et al., 1973; Maggi, 
1991). Tachykinin NK1 receptor seems more commonly found in blood vessels and the 
urothelium than in muscle cells (Candenas et al., 2005). NK2 receptors are present in 
detrusor muscle (Templeman et al., 2003). PACAP- immunoreactivity is present 
primarily in afferent neurons. Exogenous PACAP has both relaxant and excitant effects 
on bladder and urethral smooth muscle depending on species (Yoshiyama et al., 2008). 
Prostaglandins as one of the modulator groups are produced locally in the bladder 
urothelium and muscle layers. Exogenous PG alters bladder motor activity in vitro and 
in vivo and it can also influence the micturition reflex in humans and many different 
species as discussed before.  
 
Spontaneous contraction 
Lower urinary tract tissues especially bladder, are capable of generating a TTX 
resistant spontaneous activity (Sibley, 1984). Moreover, some reports found that 
spontaneous contractions were observed to an increased extent in OAB patients (Mills 
et al., 2000; Sui et al., 2009). The mechanisms behind spontaneous activity is not clear 
yet, although some have been proposed. 1) Neurogenic hypothesis: de Groat reported 
that reduced neurogenic inhibition could increase the activation of micturition reflex 
and contractions associated with smooth muscle overactivity (de Groat, 1997).  2) 
Myogenic hypothesis: changes to the smooth muscle excitability and intercellular 
coupling to the other muscle cells would modify the contractile activity (Brading, 
1997). In addition, pacemaker cells such as interstitial cells could generate spontaneous 
contractions (Hashitani, 2006). Oscillators located in the interstitial cells generate 
repetitive Ca2+ transients that activate inward currents. The currents spread through the 
gap junctions providing a depolarizing signal which opens L-type voltage-operated 
channels (VOCs). The result of increased Ca2+ thus triggers smooth muscle contraction 
(Berridge, 2008). 3) Urotheliogenic hypothesis: changes in the sensitivity and coupling 
of the mucosa (urothelium/suburothelium) network results in the changes of 
spontaneous activity (Ikeda et al., 2008).  
 
1.2.5 Mediator Release 
 
The bladder urothelium has long been thought to be a protective barrier between 
detrusor and urine. In the late 1980’s it was noticed that contraction responses to the 
sensory nerve mediator substance P in the guinea pig urinary bladder were smaller 
when the urothelium was intact (Maggi et al., 1987a). Direct evidence for the release 
of a relaxant mediator from bladder was obtained by Andersson’s group, when they 
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co-incubated urothelium containing urinary bladder with an endothelium-denuded rat 
aorta strip (Fovaeus et al., 1998; Fovaeus et al., 1999). Similar bladder-derived 
relaxant factor was also shown in the rat, using bladder as assay tissue by coaxial 
bioassay system (Bozkurt et al., 2004). Unlike the evidence from the previous studies 
that the relaxant factor(s) was non-urothelium dependent, Chess-Williams group 
showed the existence of a diffusible urothelium-derived inhibitory factor (UDIF) in pig 
urinary bladder by using sandwich-type bioassay experiments (Hawthorn et al., 2000; 
Templeman et al., 2002). UDIF related effects were also observed in mouse urinary 
bladder by using electrophysiology (Meng et al., 2008) and by quantitative analysis 
of contractile responses in human urinary bladder (Chaiyaprasithi et al., 2003). The 
nature of the bladder-derived non-urothelium dependent relaxant factor(s) and UDIF 
have not been elucidated. One substance group to be considered is arachidonic acid 
derivatives from the cyclo-oxygenase (COX) system. Experiments in urothelium-
intact and -denuded preparations had shown that COX products had a role in 
regulation of ureteral motility (Mastrangelo et al., 2007). The data suggested that 
prostacyclin was released from the urothelium, but they furthermore suggested that 
this to a great extent acted indirectly, via stimulation of the release of an unknown 
inhibitory factor.  
 
1.3 PROSTANOIDS AND PROSTANOID RECEPTORS 
Fatty acids as sources of energy and as precursors of mediators are usually derived 
from triglycerides or phospholipids. Eicosanoids are a group of important signaling 
molecules made by oxidation of the 20-carbon fatty acid arachidonic acid (20:4 ω 6). 
One important subclass of eicosanoids is prostanoids, consisting of prostaglandins, 
thromboxanes, and prostacyclins. Prostanoids exert their bioactivities locally via 
specific receptors. The modulatory roles of prostanoids in the lower urinary tract had 
come into focus for many years, but the mechanisms of prostanoids effects are still 
not clear due to their multitude and to lack of pharmacological tools. In recent years, 
the molecular and genetic information as well as specific agonists and antagonists of 
prostanoids receptors have become available, making it possible to evaluate the 
effects of prostanoids from a more detailed perspective. In this study, we focused on 
biosynthesis and bioactivities of prostaglandin D2 and E2 in the lower urinary tract. 
 
1.3.1 Prostanoids Biosynthesis 
Eicosanoids can be metabolized from arachidonic acid (AA) through enzymatic or 
non-enzymatic processes. There are three major well known enzymatic pathways 
catalyzed by cyclo-oxygenase (COX), lipoxygenase (LOX), and cytochrome P450 
(epoxygenase, CYP) respectively (Buczynski et al., 2009). In addition, prostaglandin-
like compounds called isoprostanes are formed via non-enzymatic process where free 
radicals act on AA. Prostanoids that are synthesized via cyclooxygenase pathways are 
a group of hydroxyl fatty acids containing an oxygenated cyclopentane unit. PGH2 as 
the precursor for prostanoids is formed from free AA by prostaglandin endoperoxide 
synthases known as constitutively expressed cyclo-oxygenase-1 (COX-1) or 
inducible cyclo-oxygenase-2 (COX-2) via an unstable intermediate product PGG2. 
PGG2 is then reduced to PGH2 in the peroxidase active site. PGH2 is rapidly 
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converted to prostaglandin D, E, F, and I series and to thromboxane A2 via 
prostaglandin D, E, F, I synthases and thromboxane synthase (Smith et al., 2000). 
(Figure 4) 
 
 
Figure 4. Schematic overview of prostanoids synthesis in the cyclooxygenase pathway 
and the corresponding prostanoid receptors. Prostanoid synthases nomenclature is 
from the IUPHAR database (http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=243). 
 
1.3.2 Prostanoid Receptors 
Based on the IUPHAR prostanoids receptors classification updated in year 2009, there 
are nine prostanoids receptors classified as DP1, DP2 (CRTH2), EP1, EP2, EP3, EP4, FP, 
IP, and TP preferentially activated by the major prostanoids PGD2, PGE2, PGF2α PGI2 
and TxA2 (Woodward et al., 2011) (Figure 4). Some receptors such as EP3 have several 
splice variants. Moreover, ligand binding specificity studies have shown that 
prostaglandins have different binding affinities not only to the corresponding receptors 
but also to the other prostanoid receptor subtypes (Kiriyama et al., 1997). Primary G 
protein coupling studies classified DP1, EP2, EP4 and IP receptors as Gs-coupled 
receptors. EP1, FP and TP receptors were shown to be Gq-coupled, while EP3 receptors 
seemed capable of coupling both Gq and Gi proteins. In smooth muscle, activation of 
Gs-coupled receptors leads to the increase of intracellular cAMP levels, thereby 
activating protein kinase A (PKA) which could phosphorylate myosin light chain 
kinase resulting in smooth muscle relaxation. Activation of Gq-coupled EP1, FP and TP 
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receptors could increase the level of second messenger intracellular Ca2+ concentration, 
leading to contractile responses. EP3 receptors can couple Gi protein to decrease the 
cAMP level and couple Gq protein to increase the intracellular Ca2+ concentration. 
Activation of EP3 receptors in the smooth muscle would thus induce a contractile 
response. Studies on DP2 receptor signaling pathways are limited. DP2 receptors are Gi-
coupled which may decrease the intracellular cAMP level and cause Ca2+mobilization 
(Woodward et al., 2011). 
 
1.3.3 Prostanoids and LUT 
1.3.3.1 Production of prostanoids in the LUT    
It is well established that prostanoids are produced locally within the bladder smooth 
muscle and mucosa in human and other species (Abrams et al., 1979; Jeremy et al., 
1987; Andersson, 2009). Their production increases by various stimuli under 
pathological conditions such as bladder outlet obstruction (Park et al., 1997b; Masick et 
al., 2001), spinal cord injury induced bladder overactivity (Masunaga et al., 2006) and 
inflammation (Saban et al., 1994; Wheeler et al., 2001; Wheeler et al., 2002). The 
production of prostanoids also responds to physical stretch (Downie et al., 1984; 
Jeremy et al., 1984) and EFS of urinary bladders strips in vitro (Alkondon et al., 1980).  
Although the prostanoid effects differ slightly between different species, prostaglandin 
E, F series and thromboxane usually contract bladder strips and increase the 
spontaneous activities during in vitro experiments (Abrams et al., 1975; Andersson et 
al., 1977; Ueda et al., 1985; Palea et al., 1998). In in vivo experiments, urodynamic 
tests showed an increased detrusor pressure and reduced bladder capacity after 
intravesical administration of PGE2 (Schüssler, 1990; Ishizuka et al., 1995; Schröder et 
al., 2004). The mechanisms that, apart from inflammation, increase prostanoids 
production are unclear. They could be neuronal, hormonal or via a local reflex. . 
 
In addition to release of the prostaglandins E and F series, some release studies also 
showed significant release of PGD2 from pieces of normal rat urinary bladder (Kasakov 
et al., 1985; Whigham et al., 2002) and from guinea pig urinary bladder after 
ovalbumin sensitization or dietary fat supplementation (Saban et al., 1994; Whigham et 
al., 2002). Whether PGD2 also plays a role in regulating bladder muscle contractility 
has not been reported. In this study, we not only measured the release and recovery of 
PGD2 from the whole urinary bladder but also for the first time investigated PGD2 
effects in modulating guinea pig lower urinary tract motility (Paper II, III and IV). 
 
1.3.3.2 Prostanoids bioactivity and receptors in the LUT 
Expression of all EP1 EP2 EP3 and EP4 receptor subtypes have been shown in guinea 
pig urinary bladder (Ponglowhapan et al., 2010; Rahnama'i et al., 2012a). No data 
suggests expression of DP, FP and IP prostaglandins receptors (Rahnama'i et al., 
2012b). Other than expression investigations, there are some mouse knockout studies 
and pharmacological studies dealing with the function of different receptor subtypes in 
urinary bladders. One study using EP1 knockout mice showed that, compared with wild 
type, EP1 knockout mice did not respond to intravesical PGE2 instillation (Schröder et 
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al., 2004). In normal rats, an EP1 antagonist significantly increased the bladder 
capacity, voiding volume and micturition interval (Lee et al., 2007). Urodynamic tests 
of EP3 knockout mice revealed an enhanced bladder capacity in the basal state and 
reduced hyperactivity response to application of PGE2 (McCafferty et al., 2008). In 
rats, intravesical instillation of the EP4 antagonist MF191 suppressed the bladder 
overactivity induced by PGE2 but had no significant effects on control responses 
(Chuang et al., 2012). No data was found concerning the expression of DP receptors or 
the effect of PGD2 and its receptors involved in the urinary bladder except one human 
data set that suggested PGD2 to have a low potency to contract bladder strips (Palea et 
al., 1998). In the respiratory system, PGD2 was found to be a potent mediator, exerting 
biological excitatory and inhibitory effects through DP1, DP2 receptors, and was also 
able to activate TP receptors (Larsson et al., 2011). Expression of DP receptors in 
guinea pig esophageal nodose ganglia was reported by Zhang and colleagues by use of 
immunohistochemistry, Western blotting and RT-PCR (Zhang et al., 2013).  
 
Effects of PGE2 on bladder trigone and proximal urethra have been studied for decades. 
Andersson and colleagues showed that PGE:s relaxed pre-contracted human circularly 
cut urethral rings (Andersson et al., 1977). PGE2 was shown to relax the pre-contracted 
trigone and longitudinally cut urethra in the human and pig (Klarskov et al., 1983a). 
Similar results were also shown in other species, that PGE2 relaxed the pre-contraction 
of circularly cut hamster and longitudinally cut dog urethra (Mutoh et al., 1983; Pinna 
et al., 1998). In one study of cat urethra, PGE2 contracted the longitudinal urethra strips 
but relaxed the circular urethral muscle (Abdel-Hakim et al., 1983). In animal 
experiments using rabbit and dog trigone, PGE2 contracted the tissue and increased 
spontaneous activities (Mutoh et al., 1983; Gotoh et al., 1986). So far, there is no data 
available on the effect of PGD2 in trigone and proximal urethra. Whether PGD2 is 
involved in the regulation of trigone and urethra motility and if there is expression of 
DP1 and DP2 receptors in these regions have until now been open questions. 
 
1.3.3.3 PGD2 in other systems 
PGD2 has a variety of biological roles via CRTH2 (DP2), DP1 and TP receptors. Effects 
of Gi-coupled CRTH2 receptor activation include recruitment of Th2 cells (Honda et 
al., 2003; Xue et al., 2005) and eosinophils (Woodward et al., 1990; Hirai et al., 2001; 
Monneret et al., 2001) resulting in production of cytokines . Gs-coupled DP1 receptor 
activation induces inhibition of platelet aggregation (Whittle et al., 1983; Trist et al., 
1989), bronchodilatation (Matsuoka et al., 2000) , vasodilatation (vary according to 
species) (Giles et al., 1989), tocolysis (Senior et al., 1992; Fernandes et al., 1995), and 
is implicated in central regulation of sleep (Urade et al., 1999) and in pain (Eguchi et 
al., 1999). Suppression of cytokine production, via DP1 activation in inflammation and 
immune responses, occurs in certain leukocytes and in dendritic cells (Hammad et al., 
2003). The effects of DP1 activation in inflammation and immune responses are usually 
accompanied by DP2 activation in an opposing fashion. This could switch PGD2 from a 
pro- to an anti-inflammatory mediator. PGD2 can also bind to the Gq-coupled TP 
receptor. Activation of TP receptors results in platelet aggregation, bronchoconstriction 
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and vasoconstriction (Pettipher et al., 2007), and PGD2 can either by itself or via its 
metabolites exert TP-mediated airway constriction (Coleman et al., 1989). 
 
PGD2 is biosynthesized in brain, platelets, mast cells and some neoplastic cells, and is 
rapidly metabolized by 15-hydroxy prostaglandin dehydrogenase (15-hydroxy PGDH) 
and 11-ketoreductase (AKR1C3) to 13,14-dihydro-15-keto PGD2 (DK-PGD2) and 9α, 
11β-PGF2. Alternatively, through non-enzymatic means, PGD2 is converted to J-ring 
products PGJ2, ∆12-PGJ2, 15-deoxy-∆12,14-PGJ2 (15d-PGJ2) or the D-ring products 
∆12-PGD2, 15-deoxy-∆12,14-PGD2 (15d-PGD2). Conversion of ∆12-PGD2 and ∆12-
PGJ2 from PGD2 and PGJ2 are albumin-catalyzed isomerization processes (Fitzpatrick 
et al., 1983; Shibata et al., 2002). (Figure 5) Although a micromolar range of ligand 
concentrations was used to generate intracellular effects, some of these metabolites 
might be endogenous agonists on CRTH2 and DP1 receptors (Pettipher et al., 2007). 
The influence of PGD2 metabolites in the LUT under physiological and 
pathophysiological conditions is unknown. 
 
 
Figure 5. Schematic overview of PGD2 metabolism. PGD2 spontaneous by dehydrates 
to PGJ2, which can undergo a second dehydration to generate 15d-PGJ2. 15d-PGD2, 
15d-PGJ2 and ∆12-PGD2 and ∆12-PGJ2 are agonists for CRTH2 receptor (Monneret 
et al., 2002; Heinemann et al., 2003; Gazi et al., 2005). 15d-PGJ2 is the most studied 
PGD2 metabolite, and can bind to both DP1 and DP2 receptors. The main target of 
15d-PGJ2 is peroxisome proliferator-activated receptor-γ (PPAR-γ)(Bell-Parikh et al., 
2003). Activation of PPAR-γ in turn mediates anti-inflammatory effects. 9α,11β-PGF2 
might be an agonist of the Gq-coupled TP receptor, activation of which leads to airway 
contraction (Beasley et al., 1987). 9α,11β-PGF2 can also activate CRTH2 receptors 
(Sandig et al., 2006). 
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2 HYPOTHESIS AND AIMS 
 
The general project aims at gaining a further understanding of the Overactive Bladder 
Syndrome. The main hypothesis was that, if proven to exist, the urothelium-derived 
inhibitory factor (UDIF) would be of importance in normal bladder function and if 
chemically identified could be shown to be disturbed in overactive bladder. The main 
aims were: 
 
1. To investigate whether guinea pig urothelium-derived inhibitory factor could be 
demonstrated by in vitro serial bioassay and to attempt its chemical 
characterization. 
 
2. To analyze whether adenosine/purinergic P1 receptor agonists, nitric oxide or 
prostaglandins might explain any observed activity. 
 
 
During chemical analysis of the observed UDIF activity we found considerable 
amounts of prostanoids released from guinea pig urinary bladder, with a PGD2-like 
component. As a consequence of obtained results the following aims were formulated: 
 
3. To identify and quantify the release of prostaglandins under physiological 
conditions and to investigate the activity of PGD2 in modulation of bladder 
motility. 
 
4. To study receptors involved in PGD2 action on the bladder and their distribution.  
 
5. To investigate whether PGD2 might affect the bladder outflow region. 
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3 METHODS 
 
3.1 TISSUES PREPARATION 
Albino guinea pigs of either sex weighing 300 to 800 g were anaesthetized with 
midazolam 1 mg kg-1 + sodium pentobarbital 120 mg kg-1 and exsanguinated. 
 
PAPER I: The kidneys, ureters and urinary bladders of guinea pigs were removed en 
bloc. The proximal ureter about 2 cm long with part of the renal pelvis was removed. 
The pelvic-ureteral preparations were cut open longitudinally, and in some preparations 
the urothelium was removed by scraping with a blunt instrument. Guinea pig bladders 
were kept intact and everted. In some experiments the bladder 
urothelium/suburothelium, which accounts for approximately one third of the thickness 
of the bladder wall, was removed as far as possible by cutting with scissors. Removal 
of the urothelium was after experiments confirmed by NADPH-diaphorase staining.  
 
PAPER II: The abdominal aorta was perfused with warm saline in order to achieve 
blood-free tissue preparations. Then the urinary bladder was removed and cleaned from 
fat and connective tissue. Two kinds of preparations were made. For the release 
experiments, the whole bladder was spirally cut into a 2-3 cm long strip. For bioassay 
and pharmacological studies, one single bladder dome was cut into several 8 X 2 mm 
strips. In some experiments, the bladder urothelium was removed as much as possible 
by fine dissection with iris scissors and forceps under the microscope. Differential 
assay was performed also on guinea pig colon longitudinal strips prepared as previously 
described (Olgart et al., 1998). 
 
PAPER III: The urinary bladder was separated from the urethra and ureters. Detrusor 
from bladder dome was cut into several strips. Urothelium was either intact or removed 
as described before.  
 
PAPER IV: Male guinea pig urinary bladder and proximal urethra were taken en bloc. 
The bladder trigone was dissected by locating the urethra and ureter openings. A 
trigone strip about 7 X 2 mm was made from each guinea pig with the urothelium 
intact. The proximal urethra was cut into several rings with urothelium intact. Urethral 
rings were then cut open into strips for organ bath experiments. 
 
After dissection, tissues were placed in a storage bath for equilibration for 30-60 min 
in Tyrode′s solution (136.9 mM NaCl, 4.8 mM KCl, 23.8 mM NaHCO3, 0.5 mM 
MgCl2, 0.4 mM NaH2PO4, 2.5 mM CaCl2, and 5.5 mM glucose) and aerated with 5% 
CO2 in O2 at 37℃. 
 
3.2 CASCADE SUPERFUSION 
PAPER I. Three water-jacketed and thermostatted chambers were mounted in series. 
The top chamber was preceded by a warming coil through which was pumped aerated 
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(5% CO2 in O2) Tyrode′s solution at 1.5 mL per min by means of a Gilson peristaltic 
pump. The fluid was led onto the tissues via the suspending cotton ligature. In the 
upper chamber the donor tissue, a whole guinea pig bladder, was connected to an 
isometric transducer (FT03, Grass Instruments, Quincy, MA). The initial tension of 
the bladder was adjusted to 20 mN. An assay ureter with one end connected to 
Harvard isotonic transducers (Harvard Apparatus, Holliston, MA) was mounted in 
each of the two lower chambers. The distance between the donor tissue and the assay 
tissue in two chambers was 20 cm. The time required for flow to travel between donor 
and assay tissues was approximately 3 s (Figure 6). 
Carbachol was introduced either by injection onto tissues directly or infusion into the 
supplying flow just before the donor chamber. By infusion at the bottom of the donor 
chamber, compounds such as scopolamine could be directly infused onto assay tissues, 
thus bypassing the donor tissue. Blocking agents (L-NAME, 8-PST or diclofenac) were 
added into the superfusion reservoir separately and exposed to the tissues for at least 30 
min before carbachol application. 
 
           
  
Figure 6. Schematic drawing of the employed cascade serial superfusion, based on 
the Vane technique.(Supporting Figure S1, Paper I; modified from(Gryglewski et al., 
1986). 
 
3.3 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
PAPER II. Superfusate of the urinary bladder was for 66 min collected after the donor 
chamber onto 35cc Sep-Pak tC18 cartridges (Waters) or directly collected as 15 mL 
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fractions in ice-cold test tubes with acetic acid (2% final concentration). Superfusate 
samples were analyzed by two steps of reversed phase HPLC, first using a C18 column 
(150 x 8 mm, particle size 5 µm; ReproSil-Pur C18-AQ, Dr Maisch GmbH, 
Ammerbuch-Entringen, Germany). The gradient profile was from water to 50% 
methanol in 10 min, 50 to 80% methanol in 60 min and 80 to 100% methanol in 10 min 
with 1% acetic acid throughout. The flow rate was 1.6 mL min-1. Column eluate was 
monitored at 265 nm and 287 nm by two detectors and a scanning diode array UV 
absorbance detector (Waters 991, scanning the range 190-500 nm at 5 s intervals) in 
series. Eluate from the HPLC was collected as 1.5 min fractions in polyethylene test 
tubes. Fractions were dried by overnight by vacuum centrifugation and then analysed 
further in a second step of HPLC. The second purification step was by isocratic elution 
in reversed phase HPLC. The stationary phase was a C18 column (150 X 2 mm, 
particle size 5 µm; Kromasil 100 C18, Dr Maisch GmbH, Ammerbuch-Entringen, 
Germany). The mobile phase was 36% acetonitrile and 1% acetic acid at a flow rate of 
0.45 mL min-1. UV absorbance was monitored at 290 nm by a fixed-wavelength 
detector and at a 190-500 nm by the scanning UV absorbance detector (Waters 991). 
Eluate from this HPLC was collected in 0.5 min fractions in polyethylene test tubes. 
The fractions were freeze-dried overnight and then immediately bioassayed on bladder 
detrusor smooth muscle preparations. Standard compounds were analyzed under the 
same conditions in the HPLC system for comparison of retention times and calculations 
of recovery. 
 
3.4 MEASUREMENTS OF NO/NO2
- BY CHEMILUMINESCENCE 
PAPER I. The superfusate of the guinea pig urinary bladder tissue was collected 
during periods of 1 min before and during ACh stimulation. The NO-synthase 
substrate L-arginine (10-5 M) was added to the Tyrode′s solution, in order to maintain 
the synthesis of NO during collection. Aliquots of 1 mL were injected into a reaction 
glass chamber, containing 100 mL to 150 mL of 1% sodium iodide in deoxygenated 
and concentrated hot (89°C) acetic acid. In the acidic and reducing milieu, NO2
- is 
reduced to NO (Walters et al., 1987) which is by a stream of N2 carried into a reaction 
chamber. In the reaction chamber NO together with ozone reacts under vacuum 
giving rise to photons, the amount of which is counted by a photo- multiplier (Palmer 
et al., 1987; Walters et al., 1987). The detection limit was 0.5-2 pmol NaNO2 per mL. 
The system was calibrated by injecting freshly made aliquots of NaNO2 solution and 
using peak heights for construction of standard curves for calculation of unknown 
samples (Wiklund et al., 1993; Hallén et al., 2007). 
 
3.5 ORGAN BATH EXPERIMENTS 
PAPER II. Bladder strips were mounted vertically in 3.5 mL organ baths with one end 
fixed to a hook at the bottom of the bath and the top end connected to an isometric 
transducer. The initial tension was adjusted to 10 mN. Electrical field stimulation (EFS) 
was applied to the preparations by means of two platinum electrodes on the walls of the 
organ baths (50 V, single pulse of 0.2 ms every 30 s). The evoked contractile responses 
were recorded with a computerised acquisition system (MP100, Biopac). When stable 
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contractile responses developed, diclofenac 10-6 M was given to the tissue. After 1 h 
equilibration, PGE2, PGD2 and the freeze-dried fractions from the HPLC were applied 
and assayed onto the bladder strips in organ baths. 
 
PAPER III. Urothelium denuded bladder strips of either gender were transferred to 2.5 
to 6.5 mL organ baths to pharmacologically study the effects of PGD2 and its receptors, 
using agonists and antagonists on isolated bladder strips. Tissues were stimulated 
electrically and pretreated with diclofenac 10-6 M as in Paper II. When stable 
contractile amplitudes developed, PGD2 and the selective DP1 agonist BW-245C were 
applied to the tissue. When investigating the effects of prostaglandin receptor DP1 and 
TP antagonists, tissues were exposed to these antagonists alone or combined for at least 
one hour due to high lipophilicity/slow onset properties of prostaglandin receptor 
blockers used in this study (Jones et al., 2011). Agonist dose-response curves were then 
carried out in the presence of different concentrations of receptor antagonists. 
 
PAPER IV. Male urothelium intact trigone and proximal urethra rings, prepared into 
strips, were mounted in the organ baths. The initial tension of the trigone and urethra 
strips was adjusted to 5 mN. When stable tension developed, EFS (50 V, 15 pulses of 
0.2 ms every 60 s) was applied to trigone strips. Proximal urethra ring strips were after 
initial tests left unstimulated to record the spontaneous contractions. Upon stabilization, 
PGE2 and PGD2 were applied cumulatively to the tissues in half-log increments. 
 
The corresponding solvent used to dissolve agonists and antagonists was given to 
tissues in the same way without compounds dissolved in it. The final concentration of 
solvent used in each organ bath was less than 0.1% ethanol. 
 
3.6 WESTERN BLOT 
PAPER III. Guinea pigs were anesthetized and the descending aorta was perfused with 
30-40 mL warm saline after which the bladder dome was isolated as described above. 
Separate tissue samples of either intact wall, urothelium with suburothelium, or muscle 
were prepared. For protein extraction, each mg wet tissue was subjected to 20µL of 
lysis buffer with protease inhibitors followed by homogenization. 50 μg of proteins was 
loaded into each well of 8-16% SDS gels followed by electrophoresis. Proteins were 
transferred onto PVDF membranes subsequently probed 1 h at room temperature with a 
anti-human hematopoetic prostaglandin D synthase antibody, a anti-human DP1 
receptor antibody or a mouse IgG1 anti-human β-actin antibody. HRP-conjugated 
secondary antibodies and a chemiluminescent substrate were used to detect protein 
signal on autoradiographs (Kodak X-Omat).  
 
PAPER IV. Male guinea pigs were anesthetized as above and the bladder trigone, neck 
and proximal urethra were dissected and isolated apart. Protein extraction was prepared 
as above. 7 μg of protein was loaded onto 8-16% SDS gels and separated by 
electrophoresis. Membranes were probed overnight with rabbit anti-human DP1 
receptor antibody or rabbit anti-human DP2 (CRTH2) receptor antibody. For protein 
signal detection, HRP-conjugated secondary antibodies were used as above. 
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3.7 MORPHOLOGICAL STUDY 
PAPER I. NADPH-diaphorase staining.  
To confirm successful removal of urothelium from ureters and bladders, the whole 
preparation of urothelium-intact and -denuded ureters and bladders were incubated at 
pH 8 in Tris-HCl buffer solution containing 1 mM β-NADPH, 0.5 mM nitroblue 
tetrazolium and 0.2% Triton X-100 at 37°C for 10 min (Persson et al., 1999). Tissues 
were then washed in saline and directly placed onto slides for microscopic observation.  
 
PAPER III. Guinea pigs were anesthetized and blood-free tissues obtained as above. 
The bladder dome tissues were fixed for 4 h at 4°C in ice-cold 4% paraformaldehyde 
0.1 M phosphate buffer. After fixation, tissues were cryoprotected with sucrose solution 
for 16 to 20 h and then quickly frozen in cooled isopentane and stored at -80°C. 10 µm 
transverse bladder dome sections were mounted on coated slides and labeled with an 
anti-human hematopoetic prostaglandin D synthase antibody or a polyclonal antibody 
raised against human DP1 receptor C-terminal. To visualize the basal membrane, 
sections were incubated with an anti-laminin antibody. The sequential control sections 
were treated with blocking buffer without primary antibody. Sections were washed 
followed by application of secondary antibody labeled with ALEXA Fluor 568. 
Fluorescein isothiocyanate-labelled phalloidin or a Cy3 conjugated anti-α-smooth 
muscle actin antibody were applied followed by secondary antibody and nuclei 
counterstaining. The sections were then mounted with mounting medium and covered 
with cover slips. 
 
PAPER IV. Blood-free male guinea pig urinary bladder trigone and proximal urethra 
were prepared, fixed and sectioned as in Paper III. Sections were either labelled with 
antibody raised against human DP1 receptor C-terminal or labelled with antibody raised 
against human DP2 (CRTH2) receptor. Counterstaining of smooth muscle actin, F-actin 
and nuclei was by anti-α-smooth muscle actin antibody, phalloidin and Hoechst33258 
respectively. Secondary antibodies were applied, followed by mounting and 
fluorescence immunohistochemistry. 
 
All immunolabeled sections in Paper III and IV were observed under an Axioplan 2 
imaging fluorescence microscope (Carl Zeiss) and photographed with a Nikon D3000 
digital camera. 
 
3.8 STATISTICAL ANALYSIS 
All the data were presented as means ± standard error of the mean (SEM). Statistical 
significance was analyzed by Student's paired or unpaired t-test, or by one-way 
analyses of variances (ANOVA). A p-value less than 0.05 was considered significant. 
Agonist and antagonist characteristics such as EC50, IC50, maximal effect values and 
pA2 values were calculated by Prism software (GraphPad Software Inc). 
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4 RESULTS AND DISCUSSION 
 
4.1 UROTHELIUM DERIVED INHIBITORY ACTIVITY (PAPER I, II). 
Urothelium being one of the key elements throughout the whole project, its presence 
or absence matters. To confirm the removal of urothelium from guinea pig ureters and 
bladders, NADPH-diaphorase staining followed by imaging in reflective light was 
carried out. Several staining techniques were investigated but yielded poor or no 
staining of the urothelium whereas the NADPH diaphorase reaction exhibited 
prominent staining of the urothelium (Figure 7). The difference between urothelium 
intact and urothelium denuded areas was clearly visible, allowing confirmation of 
successful urothelium removal in urothelium-denuded bladders and ureters. 
 
Figure 7. NADPH-diaphorase staining of guinea pig ureters after a cascade 
superfusion experiment and of strips from intact and denuded bladder. Left image: 
ureters were opened longitudinally with their originally internal side facing towards 
the viewer. Top tissue was denuded from urothelium as much as possible. Urothelium 
was stained dark blue by the diaphorase reaction (bottom tissue, and some small 
specks in top tissue). Non-urothelium tissue exhibited light purple staining (top 
tissue). Some urothelium fell off from urothelium-intact tissue in the renal pelvis part 
(lower tissue), but the majority of urothelium was still present on the surface. Right 
image: two strips dissected from the same bladder with the internal side facing 
towards the viewer, one strip with urothelium intact, one removed of urothelium. 
Strips were exposed to the same diaphorase reaction as ureters and a clear difference 
was seen between the strips. When immersing the urothelium-intact bladder in the 
dye, the urothelium was folding, like when the bladder is empty, causing poor 
penetration of the dye into foldings (white streaks between dark blue). (Figure 6, 
Paper I)  
 
Urothelium-derived inhibitory factor (PAPER I) 
Guinea pig ureters exhibited regular spontaneous contractions when superfused by 
Tyrode s´ solution at 1.5 mL min-1 (Figure 8, lower panel). The spontaneous activities 
were phasic contractions at a rate of 0.5-1.5 beats min-1 and were relatively stable 
over 1 to 2 h and then declined in both frequency and amplitude, which is a 
phenomenon more prominent in urothelium-intact ureters. Urothelium-derived 
inhibition of ureter spontaneous contractions was observed by using the cascade serial 
superfusion system (Figure 6). Guinea pig whole urinary bladder was mounted in the 
donor tissue bath, urothelium-denuded ureters were the assay tissues. After 
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applications of carbachol 5x10-6 M 0.5 mL directly to scopolamine-treated 
urothelium-denuded ureters, either no effects or only excitatory effect was seen, 
whereas the same amount of carbachol injected over the urothelium intact bladder, 
subsequently reaching the ureter, showed significant inhibition of assay ureter 
contractions, sometimes preceded by an initial excitation (Figure 8). The inhibitory 
effect was reproducible by repeated injections of carbachol. The time course of 
inhibitory effects was somewhat slow. 
 
 
 
 
 
Figure 8.Experimental 
recording of an everted 
urothelium-intact bladder 
(upper tracing) and an 
urothelium-denuded ureter 
(lower tracing) in the cascade 
superfusion mode. (Figure 1, 
Paper I) 
 
 
 
 
In order to investigate whether the observed transmissible inhibitory activity was 
emanating from the urothelium, the same experiment was performed but using an 
urothelium-denuded bladder as donor tissue. No inhibition of assay ureter 
contractions was seen indicating the source of inhibitory activity to be the urothelium. 
Adenosine and nitric oxide exert inhibitory actions on smooth muscle and are well 
known inhibitors in the urinary tract (Canda et al., 2007). Also prostaglandins can 
inhibit the peristalsis of ureters and may also be very important in maintaining 
spontaneous activity of the ureter (Davidson et al., 2000). We investigated if the 
transmissible inhibitory activity was due to one of these well-known compounds. 
Nitric oxide synthase inhibitor (L-NAME), adenosine receptor antagonist (8-PST) or 
cyclo-oxygenase inhibitor (diclofenac) were added separately into the superfusion 
reservoir. In the presence of blocker, the same superfusion experiments were repeated 
as described before. The treatments had a tendency of slightly lowering the 
spontaneous contractions of the ureters, but no modification of the transmissible 
inhibitory activity was observed (Figure 9). 
 
Based on study II, we know that the bladder was able to synthesize PGE2 and PGD2, 
and that PGD2 could inhibit the bladder. However, diclofenac removed the release of 
prostaglandins from the bladder (Paper II), showing that diclofenac was effective in 
this respect. Thus, it is unlikely that the unknown inhibitory factor derived from 
urothelium is PGD2 or PGE2. 
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Figure 9. Effect of transmissible urothelium 
derived activity on ureter contractions in 
different treatment groups (n=8). ** 
denotes p<0.01 after unpaired t-test for the 
comparison between bypass urothelium 
intact (UI) bladder group with over UI 
bladder groups. # denotes no significant 
difference between antagonist/inhibitor 
treatments. Ureters in carbachol bypass UI 
bladder group exhibited similar effect as 
carbachol perfusing over urothelium 
denuded (UD) bladder group (P>0.62). 
(Figure 4, Paper I) 
 
 
Prostaglandin actions were blunted when urothelium was intact (PAPER II) 
In the organ bath, exogenous PGE2 and PGD2 effects on the nerve stimulated guinea 
pig bladder strip contractions were compared under different conditions. In the 
presence of urothelium, PGE2 and PGD2 were less effective in modulating bladder 
motility compared with in the absence of urothelium. Removal of urothelium and 
application of cyclo-oxygenase inhibitor to a similar degree modified PGE2 and PGD2 
effects (Figure 10), these being larger when the endogenous prostanoids production 
was abolished. This is in similarity with exogenous adenosine which is more 
efficacious when endogenous adenosine has been blocked (Nilsson et al., 2010).  
 
 
 
Figure 10. Contractile responses to EFS in guinea pig urinary bladder detrusor strips. 
Dose-response curves of (A) PGE2 enhancing effect and (B) PGD2 inhibitory effect on 
the contractile response. Data from 6 to 10 strips from at least 4 animals, and 
presented as mean±standard error mean (SEM). # denotes p<0.005 and * denotes 
p<0.05 for comparison of maximal response. (Figure 6A and C, Paper II) 
 
4.2 QUALIFICATION OF MEDIATOR RELEASE (PAPER I, II). 
Bladders are able to generate and release many bioactive compounds (Birder et al., 
1998; Knight et al., 2002; Tanaka et al., 2011). The cascade superfusion results in 
Paper I showed that there was an inhibitory factor(s) released from guinea pig 
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urothelium which was unlikely to be one of the known compounds, such as NO. In 
order to confirm that L-NAME was sufficient to block the NO generation, 
measurements of NO/nitrite release before and after L-NAME were carried out. The 
results showed that 3x10-4 M L-NAME was able to reduce the NO production by 
around 80%, rendering NO unlikely to be the released inhibitory factor. (Figure 5, 
Paper II) 
 
During our analysis of the urothelium-derived inhibitory factor, we found significant 
amounts of bioactivity being released from bladder urothelium, and when the HPLC 
fractions initially were bioassayed an excitatory activity was observed. We therefore 
subjected excitatory fractions from the gradient elutions to isocratic separation (Kunz et 
al., 2002) as shown in figure 11B. Subsequent bioassay on isolated urothelium-denuded 
bladder tissues revealed an excitatory activity corresponding to the retention time of 
authentic PGE2 and an inhibitory activity corresponding to the retention time of PGD2. 
 
 
Figure 11. Isolation and 
purification of excitatory and 
inhibitory prostaglandin-like 
bioactivity from guinea pig 
urinary bladder. (Figure 1, 
Paper II) 
(A) Gradient HPLC 
chromatograms of guinea pig 
urinary bladder superfusate 
collected from an urothelium 
intact urinary bladder 
(SAMPLE) and elution profile 
of a run with a sham tissue 
(BKGD).  
(B) Purification and isolation 
by isocratic reversed phase 
chromatography of excitatory 
activity fractions obtained at 
48 min from gradient HPLC 
as in panel A (SAMPLE) and 
compared with standard 
PGE2 and PGD2 (STD).  
 
 
 
Removal of the urothelium abolished more than 90% of PGE2 release, and essentially 
all of PGD2 in the sense that it now was undetectable with our method. The data 
indicated that the urothelium was the main source of PGE2 and PGD2. One hour of 
diclofenac 10-7 M pretreatment abolished more than 68% of PGE2 and 94% of PGD2 
release. This validates that the released bioactivities are likely to be PGE2 and PGD2, 
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and also that the lack of effect by diclofenac on released inhibitory activity in Paper I 
is a true negative result. 
 
4.3 EFFECTS OF PGD2 AND PGE2 IN THE LUT (PAPER II, IV). 
Based on the HPLC analysis, PGE2 and PGD2 were constantly produced in the 
urinary bladder. The effects of PGE2 and PGD2 in modulating the lower urinary tract 
(the bladder dome, trigone and proximal urethra) motilities were therefore 
investigated. Results are summarized in figure 12, panel A. Dose-response curves are 
shown in figure 12, panel B to D. 
 
Figure 12. Summary (panel A) and dose-response curves of PGD2 and PGE2 effects 
(panel B to D) in guinea pig LUT. Panel B: bladder dome, panel C: bladder trigone, 
panel D: proximal urethra. Bladder dome and trigone tissues were electrically 
stimulated whereas spontaneous contractions of proximal urethra were recorded. 
PGD2 and PGE2 were applied cumulatively in log or half-log increments. Data were 
presented as mean±standard error mean (SEM), n denotes number of tissue strips in 
panel B and number of animals in panel C and D. st.M denotes striated muscle in the 
urethra.(parts of Figure 6, Paper II; Figure 2 and 3, Paper IV) 
 
Effects of PGD2 and PGE2 on acetylcholine and ATP induced contractions were also 
investigated (Paper II). In diclofenac pretreated (10-6 M) urothelium-denuded bladder 
strips with EFS turned off, acetylcholine (3x10-6 M) and ATP (10-5 M) caused 
contractions which were reproducible when repeated. Application of PGE2 (10
-8 M) 
increased the tone and also enhanced the contractile response to exogenous ACh and 
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ATP (Figure 13 panel A and C). When PGD2 (10
-8 M) was similarly applied, responses 
to exogenous ACh and ATP were significantly inhibited (Figure 13 panel B and D).  
Figure 13. Urothelium denuded guinea pig urinary bladder detrusor strips monitored 
by isometric recording of muscle responses in the absence of EFS. Original 
experimental recordings of enhancing PGE2 (panel A and C) and inhibitory PGD2 
(panel B and D) modulation of contractile responses induced by repeated applications 
of exogenous acetylcholine (ACh) or ATP, with washings indicated by w. Tissues were 
pretreated with diclofenac 10-6 M, repeated after each wash. (Figure 7, Paper II) 
 
Presently, PGD2 in addition to its inhibitory effect on contractile responses to nerve 
stimulation also inhibited the responses to the neurotransmitters acetylcholine and ATP. 
It is reasonable to conclude that PGD2 mainly acts by a postjunctional inhibitory effect. 
Whether this involves changes in membrane potential or changes in second messengers 
or both remains to be studied and additional prejunctional effects by PGE2 and PGD2 
can not be excluded from the present results. 
 
4.4 RECEPTORS INVOLVED IN PGD2 MODULATION (PAPER III). 
In guinea pig urinary bladder detrusor, the DP1 receptor antagonist BW-A868C caused 
a progressive dose-dependent reversal of the PGD2 inhibitory effect on the contractile 
responses to EFS, where first the higher concentrations of PGD2 (during BW-A868C 
10-8 M) and then all concentrations of PGD2 (during BW-A868C 10
-6 M) now evoked 
an enhancing effect on the contractile responses. The enhancement by PGD2, after 
blocking DP1 receptors with BW-A868C, was antagonized by the TP receptor 
antagonist SQ-29548 10-7 M which alone did not modify the effect of PGD2 (Figure 
14).  
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Figure 14. Cumulative dose-
response curves to PGD2, in the 
absence and presence of the DP1 
antagonist BW-A868C and/or the TP 
antagonist SQ-29548, on contractile 
responses in urothelium-denuded 
guinea pig urinary bladder detrusor 
strips evoked by electrical field 
stimulation (50 V, single pulses of 
0.2 ms every 30 s). Data presented 
as mean±standard error of the mean 
(SEM), n denotes number of tissues. 
(Figure 2, Paper III) 
 
 
 
In summary, PGD2 and PGE2 are not only released from guinea pig urinary bladder but 
are also involved in the regulation of the lower urinary tract motilities. The action and 
potency of PGD2 and PGE2 were different depending on the tissue type (Figure 12 
panel A and Table 1). PGD2 inhibition of bladder detrusor strip EFS-induced 
contractions was mediated via DP1 receptor. PGD2 also activates TP receptors, where 
this effect can only be seen after blocking of DP1 receptors  
 
Table 1. The presently estimated potency of prostanoids receptor agonists and 
antagonists in different parts of guinea pig lower urinary tract. Data from Paper II, III 
and IV. 
 
 Bladder Trigone Proximal Urethra Antagonism in Bladder 
PGE2 pEC50 8.0±0.38 (n=6) pIC50 7.05±0.27 (n=5) pIC50 7.65±0.17 (n=7)  
PGD2 pIC50 7.6±0.23 (n=8) pIC507.08±0.27 (n=6) pIC50 7.09±0.22 (n=14)  
BW 245C pIC50 8.11±0.07 (n=11)    
BW A868C* pIC50 7.68±0.28 (n=9)   pA2 8.68±0.06 (n=6) 
*Partial agonist (Liu et al., 1996). 
 
4.5 EXPRESSION AND DISTRIBUTION OF PGDS AND DP1/DP2 
RECEPTORS IN LUT (PAPER III, IV). 
PGDS and DP1 receptor in guinea pig bladder dome. The expression of hematopoetic 
prostaglandin D synthase (PGDS) and DP1 receptor protein in the guinea pig bladder 
dome were examined by Western blot. The whole bladder dome extract as well as 
dome detrusor muscle and dome urothelium extracts were exposed to anti-PGDS and 
anti-DP1 antibodies, which were the same antibodies used in the immunofluorescence 
histochemistry. Western blot showed a band slightly above 24 kD in agreement with 
the predicted of size 24 kD for the hematopoetic prostaglandin D synthase protein. In 
the guinea pig bladder dome it was mainly from the urothelium/suburothelium as 
judged from the bands in Figure 4 of Paper III. This result agrees with a strong 
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urothelium-dependency in the release of PGD2 from the guinea pig urinary bladder as 
in the Paper II. The guinea pig urinary bladder dome expressed significant levels of 
DP1 protein. Two groups of protein bands were seen with one slightly above 40 kD as 
predicted from the size of DP1 receptor protein and additional bands at around 95 kD. 
In the immunohistochemistry performed in the bladder dome, the smooth muscle was 
relatively faintly labeled with anti-PGDS antibody compared with 
urothelium/suburothelium (Figure 15A and B). Staining for actin was prominent in the 
detrusor muscle and also in vessels of the lamina propria, with only minor overlap with 
the PGDS stain (Figure 15B). The urothelium basal membrane was identified first by 
laminin staining subsequently allowing its localization from distribution of nuclei. It is 
marked by white dashed line in Figure 15A and C according to the anti-laminin in 
combination with nuclear stain results. In Figure 6C it can be seen that a basal row of 
cell nuclei line up in the urothelium just above the basal membrane laminin stain. In 
comparison, the similar lining up of nuclei allows the major PGDS stain to be 
determined as localized to the suburothelium (Figure 4F). DP1 receptors were seen in 
several cell types throughout the guinea pig urinary bladder, as visualized by the red 
stain in figure 15C and D. There was only moderate staining for DP1 receptors in the 
urothelium, and suburothelial interstitial cells-like profiles stained slightly more for DP1 
receptors (Figure 15C under dashed line). The most prominent staining for DP1 
receptors was in the detrusor muscle (Figure 15D). In the urothelial cells (Figure 15C) 
and especially in the smooth muscle (Figure 15D) the DP1 receptor localization was 
mainly to the cell membrane, although intracellular staining could also be seen.  
DP1 and DP2 receptors in male guinea pig trigone and proximal urethra. Western blot 
results found that in the male guinea pig trigone, neck and urethra, significant levels of 
DP1 and DP2 receptor proteins were expressed in whole tissue extracts. Fluorescence 
immunohistochemistry results, in sequential vertical sections of the trigone with 
transitional urothelium (u) and part of the smooth muscle (sm) layers, are shown in 
Figure 15E and F. Immunoreactivity for DP1 and DP2 receptors was seen throughout 
the trigone urothelium and smooth muscle. DP1 receptors were more prominent in the 
smooth muscle layer (Figure 15E) while DP2 receptors were more evenly distributed in 
the urothelium and smooth muscle layers but not as strong and localized as DP1 
receptors in the muscle cells (Figure 15F). The distribution of DP1 receptor in the 
proximal urethra was similar as in the trigone where fluorescence of DP1 receptor 
antibody was seen more heavily stained in the smooth muscle than in the urothelium. 
DP2 receptor immunoreactivity was also seen distributed in the proximal urethra 
urothelium and smooth muscle. The urothelium exhibited much stronger fluorescence 
for DP2 receptor compared with the smooth muscle. The border between smooth 
muscle (sm) and striated muscle (st) in proximal urethra is shown in Figure 15G and H. 
Longitudinal and circular smooth muscle layers can be identified by red label in the 
anti-α-smooth muscle actin antibody. DP1 and DP2 receptors were found both in 
smooth muscle and striated muscle components, but DP2 receptor was stained at a 
much lower degree. Merged image of muscle anti-DP1 receptor (green) and anti-α-
smooth muscle actin (red) shows strong yellow fluorescence indicating co-localization 
of DP1 receptor on the smooth muscle bundles (Figure 15G). 
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Figure 15. Transverse section showing PGDS immunofluorescence (green) in guinea pig 
bladder dome (A, B); DP1 receptor fluorescence (red) in dome urothelium (C) and smooth 
muscle (D); DP1 and DP2 receptors fluorescence (green) in trigone urothelium and smooth 
muscle (E, F); DP1 and DP2 receptors fluorescence (green) in proximal urethra smooth muscle 
and striated muscle (G, H). Nuclei were counterstained with Hoechst33258 in blue (C, D, G, 
H).Smooth muscle cells were stained with anti-α-smooth muscle actin antibody in red (B, G, H). 
Symbols legend: u denotes urothelium, su denotes the immediate suburothelium of lamina 
propria, v denotes blood vessels, sm denotes smooth muscle, st denotes striated muscle. White 
dashed line indicates the location of the urothelium basal membrane. Scale bars indicate 100 
µm in A, B, E, F, G and H, 20 µm in C and D.  
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5 GENERAL DISCUSSION 
 
5.1 INHIBITORY MEDIATORS IN LUT  
The current studies have been focused on the peripheral control of the LUT motility. As 
mentioned in the introduction, studies had shown an unidentified smooth muscle 
relaxing factor(s) being released from the bladder smooth muscle (Fovaeus et al., 1998; 
Fovaeus et al., 1999; Bozkurt et al., 2004). Subsequently a urothelium-derived 
inhibitory factor(s) had been suggested (Hawthorn et al., 2000; Templeman et al., 
2002; Chaiyaprasithi et al., 2003; Meng et al., 2008).The results from Paper I 
confirmed the existence of the urothelium-derived inhibitory activity. We could 
ascertain that the inhibitory effect seen on assay ureters was coming from bladder 
urothelium. That merely the mechanical contraction was a cause for the release of 
inhibitory bioactivity seems unlikely since, in a previous study, stimulating the bladder 
with α-adrenoceptor agonist failed to release inhibitory factor although it induced 
significant contraction of the bladder tissue (Templeman et al., 2002). High 
concentration of KCl and neurokinin A (NKA) evoked contractile responses on human 
detrusor which were not affected by urothelium removal (Chaiyaprasithi et al., 2003). 
We therefore believe that released inhibitory activity is not simply a reflection of direct 
bladder detrusor muscle contraction, but seems to be a more complicated process 
involving muscarinic receptor activation and where urothelium is a key component in 
this process. 
 
Some studies suggested that the relaxation of trigone, bladder neck and urethra was not 
only due to the inhibition of excitatory neurotransmitter release but might also involve 
the release of non-adrenergic non-cholinergic (NANC) mediator(s) (Klarskov et al., 
1983b; Hills et al., 1984; Speakman et al., 1988). Nitric oxide was suggested to be 
responsible for the NANC factor mediated relaxation (Thornbury et al., 1992; 
Werkström et al., 1995). The existence of other relaxant mediator(s) can’t be ruled out. 
Some NANC mediator candidates apart from NO and ATP will be discussed below. 
 
Neuropeptides 
Vasoactive intestinal polypeptide (VIP) had been shown to inhibit the isolated bladder 
spontaneous activities in many species including human (Larsen et al., 1981; Levin et 
al., 1981; Finkbeiner, 1983; Klarskov et al., 1984; Sjögren et al., 1985) but seemed to 
have no effect on the EFS or ACh induced contractions (Sjögren et al., 1985). 
Intravenous injection of VIP induced relaxation of dog bladder (Andersson et al., 1990) 
but had no effect on human bladder with the dose that was able to increase the heart 
rate (Klarskov et al., 1987). In the guinea pig urinary bladder, the effects of VIP were 
contradictory. Burnstock and his colleagues found that VIP produced contractions of 
isolated guinea pig bladder strips (Mackenzie et al., 1984). Other studies showed that 
VIP either had a very weak effect (Johns, 1979) or no effect (Finkbeiner, 1983; Pessina 
et al., 2001) on baseline tension, or on magnitude or frequency of contractions of 
guinea pig bladder muscle strips. VIP was also found inhibiting the noradrenaline 
contracted urethra in the rabbit, cat, pig and human (Larsen et al., 1981; Klarskov et al., 
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1984). No data suggest a VIP effect in modulating the guinea pig ureter spontaneous 
contractions, but it can’t exclude the possibility that the urothelium-derived inhibitory 
activity bioassayed on the ureter is VIP. However, it is unlikely that VIP is the 
unknown mediator since VIP has little inhibitory effect on the isolated guinea pig 
bladder. 
 
Neuropeptide Y (NPY) rich nerves were found abundant in both human (Gu et al., 
1984; Crowe et al., 1995; Dixon et al., 1997) and rat bladders (Mattiasson et al., 1985; 
Keast et al., 1989). Moderate numbers of NPY containing nerve fibers were observed 
in the pig trigone and urethra, while very few were found in the detrusor (Persson et al., 
1995). In the rat, NPY had an excitatory influence on spontaneous contractions and 
resting tone of the detrusor, and it also potentiated EFS-induced contractions but did 
not affect ACh-evoked contractions (Iravani et al., 1994). Different results were 
observed when NPY from other species was studied. Porcine and human NPY inhibited 
the EFS-induced contractions of rat detrusor, and in the rat urethra adrenergic 
transmission was primarily inhibited. The degree of inhibitory effects in the rat detrusor 
differed with human and porcine NPY (Zoubek et al., 1993). In guinea pig bladder, 
NPY had no effect on noradrenaline, ATP or α,β-methylene ATP induced contractions, 
but inhibited the NANC components of the EFS induced contractions (Lundberg et al., 
1984). The conflicting results of NPY in modulating the LUT activities could be due to 
the different amino acid sequences in the different species and these NPY-like peptides 
might have different affinity to the receptors. Since NPY has inhibitory effect in guinea 
pig bladder, the possibility of NPY being the unknown inhibitory factor in Paper I can’t 
be excluded. There is a need for investigation of the NPY-like peptides effects in 
human LUT. However, NPY seems less plausible as the urothelium-derived inhibitory 
factor since it has no effect on tone or spontaneous contractions and enhances induced 
contractions in the equine ureter (Prieto et al., 1997). 
 
Calcitonin gene-related peptide (CGRP) is a sensory neuropeptide from capsaicin-
sensitive nerves and found distributed in all bladder layers of human and many other 
species (Nimmo et al., 1988; Smet et al., 1996). CGRP effects differ according to the 
different intensity in distribution between regions of LUT even in the same species. 
CGRP was more potent and effective as inhibitor of the EFS induced contraction in the 
guinea pig bladder neck than in the dome (Maggi et al., 1988). In hamster bladder, 
CGRP also exerted an inhibitory effect in the bladder smooth muscle (Giuliani et al., 
2001), while it had no effect on modulating the rat and human bladder contractility 
(Maggi et al., 1987b; Maggi et al., 1989). Immunoreactivity studies showed that CGRP 
colocalized with tachykinin in primary sensory neurons in bladders (Ghatei et al., 1985; 
Su et al., 1986). Tachykinins exert excitatory effects in the urinary bladder in many 
species (Anderson, 1993). Stimulation of capsaicin-sensitive nerves will result in the 
release of both inhibitory peptide CGRP and excitatory tachykinin such as substance P. 
Thus, effects of combined mediator release from sensory nerves in the bladder onto the 
assay ureter might exhibit as contraction, relaxation or no effect at all. CGRP can 
inhibit induced contractile responses in the guinea pig ureter (Hua et al., 1986; Maggi 
et al., 1996) and induced spontaneous contractions in rat ureter (Maggi et al., 1987b). 
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Further investigations are needed on whether CGRP might be a urothelium-derived 
inhibitor. 
 
Prostanoids 
Prostanoids are known to be synthesized by the cyclo-oxygenases localized in the 
urinary tract. Our results using the cyclo-oxygenase inhibitor diclofenac in the 
superfusion fluid were that it did not abolish the carbachol induced transmissible 
inhibitory activity. However, prostanoids seem to play important roles in modulation of 
urinary tract motility. It was proposed that the spontaneous motility of urinary tract 
depends on local release and balance of both excitatory and inhibitory prostanoids 
(Mastrangelo et al., 2007). Meanwhile, studies also showed difficulties to fully inhibit 
the release of prostanoids from urothelium-containing bladder tissue by application of a 
cyclooxygenase inhibitor (Abrams et al., 1979). In Paper II, we observed and quantified 
the biological release of PGE2 and PGD2 from guinea pig bladder without any stimuli. 
The concentrations of endogenous PGE2 and PGD2 from donor bladder to assay ureter 
were about 1 to 2 nanomolor and were profoundly decreased by cyclo-oxygenase 
inhibitor (Paper II, Figure 4). Furthermore, the investigation of exogenous PGE2 and 
PGD2 effects on ureter spontaneous contraction indicated that with concentration of 
biologically released PGE2 and PGD2, only excitation of ureters were seen. So, 
prostanoids being the unknown inhibitor(s) seems quite unlikely, at least by generation 
from cyclo-oxygenase.  
 
Isoprostane 
Isoprostanes are prostaglandin-analoguos compounds formed in vivo through free 
radical catalyzed peroxidation of arachidonic acid. In 1990, the PGF2 like compounds 
were found from fresh plasma of normal volunteers. Formation of these compounds 
was found to occur by a non-enzymatic oxidative process (Morrow et al., 1990). Since 
then, several other classes of isoprostanes were discovered as D2-isoprostane (D2-isoP), 
E2-isoP, J2-isoP, and A2-isoP (Milne et al., 2008). The isoprostanes were able to bind to 
the normal prostanoids receptors (Kinsella et al., 1997; Audoly et al., 2000) and 
exerted similar activities as cyclooxygenase products. As a biomarker of oxidative 
stress, 8-isoprostane was shown elevated in exhaled breath condensate, plasma and 
urine in asthmatic adults and children compared to healthy controls (Montuschi et al., 
1999; Zanconato et al., 2004). Isoprostanes were also found to be involved in 
regulation of vascular smooth muscle (Fukunaga et al., 1993) and platelet function 
(Ting et al., 2010). The isoprostane 8-epi PGF2α was also shown to be synthesized in 
rabbit bladders and to cause detrusor smooth muscle contraction (Tarcan et al., 2000). 
Based on Paper II and III, PGD2 can inhibit the EFS induced or spontaneous 
contractions in guinea pig LUT. D2-isoP and PGD2 metabolites (Figure 5) are able to 
activate the DP receptors and induce similar effects as PGD2. The possibility of the 
unknown inhibitor(s) being isoprostanes can’t be excluded. 
 
5.2 PGD2 IN LUT 
The roles of PGD2 in the allergic diseases and inflammation have been widely 
discussed and are now better understood (Pettipher et al., 2007), while knowledge 
   35 
about the PGD2 effects in the LUT seems to have been minimal. One in vitro study by 
using human bladder strips showed no effect of PGD2 application up to 3x10
-7 M at 
resting tension (Palea et al., 1998). In Paper II, III and IV, the release and effects of 
PGD2 in the guinea pig bladder dome, trigone and urethra have for the first time been 
discribed. The receptors involved in the functional effects together with DP1/DP2 
distribution in LUT was also investigated for the first time. PGD2 was shown to be 
released mainly from guinea pig urothelium/suburothelium. Immunofluorescent 
detection with anti-DP1 and anti-DP2 showed that DP1/DP2 receptors were distributed 
both in the urothelium and suburothelium and DP1 prominently in the smooth muscle 
cells. Although presently not studied, in the smooth muscle cells it seems likely that 
PGD2 directly activates Gs-coupled DP1 receptors leading to the increase of intercellular 
cAMP levels, hence activating PKA which could phosphorylate myosin light chain 
kinase and result in smooth muscle relaxation. Presently, PGD2 in guinea pig urinary 
bladder was also able to inhibit the contractions induced by nerve stimulation, ACh and 
ATP, favouring the idea of a direct smooth muscle relaxing action. In the urethra, PGD2 
inhibited the spontaneous contractions which in the LUT are generally thought to be 
generated or modulated by interstitial cells (Brading et al., 2005; Brading, 2006). Some 
remaining questions are: apart from direct effect on the smooth muscle, is PGD2 
indirectly involved in the modulation of the bladder and urethra motilities through 
action on the interstitial cells? If DP1/DP2 receptors are expressed in the urothelium, 
what is the function of activating DP1/DP2 receptors located on the urothelial cells? 
(Figure 16) 
 
Figure 16. Schematic drawing summarizing the bladder structure, PGD2 released from 
urothelium and suburothelium, localization of DP1 and DP2 receptors and the effect of 
PGD2 relaxing the smooth muscle in guinea pig urinary bladder. 
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The inhibitory effect of PGD2 in modulating guinea pig LUT motility in vitro is 
valuable information to understand the pathophysiology of bladder and urethral 
sphincter. Depending on the expression and distribution of DP receptors in the LUT, 
the functions of PGD2 might be different in other animal species and the human. 
DP1−/− and CRTH2−/− mice were generated and used in many allergy and 
inflammation studies (Mohri et al., 2006; Satoh et al., 2006; Murata et al., 2013). These 
knock-out animals provide us interesting tools to further study the effects of PGD2 in 
the LUT. Moreover, there is also a need for in vivo urodynamic studies to understand 
the systematic role of PGD2 in LUT. 
 
5.3 ENDOGENOUS PROSTANOIDS AND RECEPTOR ANTAGONISTS 
Diclofenac was applied to the bladder tissue in our pharmacological experiments to 
inhibit the production of endogenous prostanoids. After applying diclofenac to a naive 
guinea pig bladder strips, less than 5% inhibition of EFS induced contractions was 
observed. After washing the diclofenac treated bladder tissues, more than 20% 
inhibition was shown which was not seen when washing naive bladder strips. This 
indicates that similar to endogenous adenosine (Nilsson et al., 2010), considerable 
amounts of endogenous prostanoids or prostanoid-like compounds are present in the 
tissues. The concentrations of endogenous prostanoids will be decisive for the effects of 
further application of exogenous prostanoids, which could be one of the reasons that 
some studies reported negative results of prostanoids application to certain tissues. I 
suggest that when working with prostanoids, removal of the endogenous prostanoids 
that have already been formed is as important as inhibition of their production.  
 
Prostanoid agonists and antagonists are a group of compounds with high affinity and 
high lipophilicity. These properties could explain the slow onsets of some prostanoid 
receptor analogs and blockers in multilayer tissues (Jones et al., 2011), which is one of 
the likely reasons why reports on estimated pA2 values of prostanoid receptor 
antagonists vary and may be distorted in the same species and same tissue. There is a 
need for caution in using highly lipophilic prostanoid receptor antagonists as research 
tools. When performing pharmacological experiments in the present studies, the 
minimal incubation time of antagonists was at least one hour, aiming for the blockers to 
exert an optimal antagonism with each given dose.  
 
5.4 PHARMACOLOGICAL IMPLICATIONS 
The framework of prostanoids and their receptors is very complicated. Ligands do not 
exclusively bind to their corresponding receptors. If follows that the receptors are not 
entirely specific for the correspondent prostanoids. Moreover, clinical studies by using 
non-steroidal anti-inflammatory drugs to treat bladder instabilities have shown 
contradictory results (Cardozo et al., 1980; Delaere et al., 1981; Chaudhuri et al., 1993; 
Park et al., 2000). It seems that globally inhibiting the prostanoids production might 
take away the excitatory factors but also inhibitory factors as well. The treatments 
should specifically aim at certain prostanoids or target at prostanoids receptors. 
Urodynamic studies showed that intravesical administration of PGE2 and PGE2-
derivative to women not only increased bladder pressure but also reduced bladder 
capacity and resulted in measurable bladder instability (Andersson et al., 1978; 
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Schüssler, 1990). Treatment targeting EP1 receptors has been attempted. A recent 
clinical phase II study using the EP1 receptor antagonist ONO-8539 to treat non-
neurogenic OAB suggested a minimal role for EP1 receptor antagonism (Chapple et al., 
2014).However, the work leading up to this trial provided concepts of targeting the 
prostanoid receptors to treat OAB. Our work revealed roles of PGD2 in regulating the 
LUT motility, which opens up new possibilities to target PGD2 signaling pathways 
when in the future designing treatments for OAB and other bladder instability 
situations. 
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6 FUTURE PERSPECTIVES 
Prostaglandin D2 as an inhibitory modulator in guinea pig lower urinary tract (bladder 
and proximal urethra), its release, synthase expression, receptor activation, receptor 
expression and pharmacological properties, has been studied and thoroughly discussed 
in the present work. The roles of PGD2 in influencing human bladder motility and the 
outflow region will be valuable future information for us to understand the physiology 
of the human lower urinary tract. To compare the effects of PGD2 in the healthy human 
lower urinary tract tissues with that in OAB patient tissues will help us to understand 
the roles of PGD2 under pathological conditions, which might lead to new treatment 
targets for overactive bladder situations. The expression and effects of inhibitory or 
relaxing prostanoid receptors are also of interest in the human tissue under both 
physiological and pathological conditions.  
 
During chemical analysis of the prostanoids released from guinea pig urinary bladder in 
Paper II, we have developed a method to minimize the abundant background of 
impurities from buffer salts and other system components. The described technique is 
generally applicable for isolation attempts of endogenous compounds. Introducing the 
use of the ureter as a bioassay tissue might prove useful in future studies on urinary 
tract signalling compounds, including UDIF, especially if combined with mass 
spectrometry methodology.  
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7 GENERAL CONCLUSIONS 
 
1. Urothelium-denuded guinea pig ureters can be used in serial superfusion to 
bioassay released inhibitory activities from the guinea pig urinary bladder.  
 
2. An inhibitory activity originates from the urothelium and is transmissible over a 
significant distance. This opens up the possibility of attempting isolation of the 
elusive urothelium derived inhibitory factor(s). 
 
3. The unknown urothelium-derived inhibitory activity is unlikely to be induced 
by or mediated through nitric oxide, adenosine receptor agonists or 
cyclooxygenase products.  
 
4. The urothelium/immediate suburothelium is a major source of PGD2 production 
and PGD2 can inhibit the bladder motility mainly through a postjunctional 
action. 
 
5. PGD2 exerts a dual action on contractile responses, with an inhibitory effect at 
relatively low concentrations through DP1 receptors localized in the smooth 
muscle, masking an excitatory effect exerted via TP receptors. 
 
6. In the guinea pig outflow region, PGD2 has an inhibitory influence on the 
trigone and proximal urethra which is consistent with the expression and 
distribution of DP1 and DP2 receptors in these regions. 
 
7. The role of PGD2 in regulation of the human bladder, and especially the 
outflow region, should be considered in future investigations, not least in the 
context of overactive bladder. 
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